Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics-Reference-Cited by-同舟云学术

Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics

Published:2019-04-24 Issue:1 Volume:84 Page:51-60
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Mistry Hitesh B.^ORCID,Helmlinger Gabriel,Al-Huniti Nidal,Vishwanathan Karthick,Yates James

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-019-03840-3.pdf

Reference27 articles.

1. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

2. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline. Eur J Cancer Oxf Engl 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026

3. Ribba B, Holford NH, Magni P et al (2014) A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT Pharmacomet Sys Pharmacol 3:1–10

4. Hata AN, Niederst MJ, Archibald HL et al (2016) Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med 22:262–269. https://doi.org/10.1038/nm.4040

5. Hede K (2013) Project data sphere to make cancer clinical trial data publicly available. J Natl Cancer Inst 105:1159–1160. https://doi.org/10.1093/jnci/djt232

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib;CPT: Pharmacometrics & Systems Pharmacology;2024-02-20

2. Understanding tumour growth variability in patient-derived breast cancer xenograft models identifies early responders and biomarkers of resistance to PARP inhibition;2024-02-13

3. Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model;Journal of Pharmacokinetics and Pharmacodynamics;2023-11-06

4. Treatment of evolving cancers will require dynamic decision support;Annals of Oncology;2023-10

5. How translational modeling in oncology needs to get the mechanism just right;Clinical and Translational Science;2021-11-12